← All trials
NCT03311178
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2014
- Primary completion
- Oct 13, 2015
- Completion date
- Oct 10, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Autonoma de MadridLead sponsor
- Tufts UniversityCollaborator
- Universidad Autonoma de MadridReponsible party - principal investigator
- University of SussexCollaborator
- Autonomous University of MadridCollaborator
- University of SussexStudy director
- University of Witten/HerdeckeCollaborator
- Gazi UniversityCollaborator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- Iuliu Hatieganu University of Medicine and PharmacyCollaborator
- Onorach Clinical LtdCollaborator
- Proveca LtdCollaborator
- Semmelweis UniversityCollaborator
- Universidad Autonoma de MadridStudy chair
- Spanish National Health SystemOverall official - principal investigator
- Basque Country UniversityCollaborator
- University of LiverpoolCollaborator
- University of LubeckCollaborator
- University of PecsCollaborator
- University of CologneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.